OOIR: Observatory of International Research

Papers

(The TQCC of Annual Review of Pharmacology and Toxicology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Introduction to the Theme “New Approaches, Technology, and Techniques That Advance Pharmacology and Toxicology”	137
Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets	135
Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays	131
How Biologics Have Changed the Drug Discovery Landscape	131
Pharmacology of Intestinal Inflammation and Repair	130
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease	121
The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases	101
Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology	94
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities	92
Evolving Approaches for Pharmacological Therapy of Obesity	81
Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment”	77
Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?	76
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development	73
E-Cigarette Toxicology	68
	68
Incretin Signaling Neighborhoods and Adverse Drug Reactions	67
Introduction to the Theme “Development of New Drugs: Moving from the Bench to Bedside and Improved Patient Care”	67
Community Aspects of HIV Biomedical Prevention	66
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer	65
Multisystem Toxicity of E-Cigarettes in Preclinical and Clinical Studies: Pathophysiologic Effects of E-Cigarette Aerosol Exposures from Head to Toe	64
The Gut Microbiome, Metformin, and Aging	63
Endocannabinoid-Based Therapies	60
Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases	59
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges	57
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss	57

G Protein–Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders	55
Gβγ Signaling: Lessons Across the Cellular Multiverse	55
GPCR Biosensors to Study Conformational Dynamics and Signaling in Drug Discovery	53
Health Digital Twins in Life Science and Health Care Innovation	52
OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory	51
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon	50
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies	50
Synthetic Cannabinoids: A Pharmacological and Toxicological Overview	49
RNA Splicing as a Therapeutic Target in Cancer	47
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation	47
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments	45
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment	39
Pharmacogenetics of Antiplatelet Therapy	39